Nanobodies are considered to be one of the best technology in the fields of research, diagnostics and therapy especially in cancer research. These technology was developed from antigen binding fragments, originating from Camelid heavy-chain antibodies. These molecules do not have light chains, which is an essential part of antibody found in humans. Based on the above finding, nanobodies molecule containing single-domain only were developed, and these molecules contain functional and structural properties similar to heavy chain antibodies. These molecules have several advantages as compared to the conventional antibodies such as small-size, nano to picomolar affinities, and multiple route of administration. Ablynx, which is acquired by Sanofi S.A., is one of the leading company in this market.
Nanobodies Market Drivers
Currently, no products are available in the market, but there are multiple products in the pipeline including few in very late stage of clinical trials. For instance, marketing authorization application for Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) has been submitted to European Medicine Agency (EMA) in February 2017. The product, Caplacizumab, is expected to be launched in Europe in 2018. Moreover, the company, Ablynx, is expected to file for biologic license agreement to the U.S. Food and Drug Administration (FDA) in 2018, and is expected to launch this product in U.S. in 2019. Both, Europe and U.S. are the key markets for any biologics including monoclonal antibodies and are expected to be the high revenue generating market for nanobodies.
Nanobodies Market Key Players
Ablynx (now part of Sanofi S. A.) is the key player in the global nanobodies market. Moreover, the company is developing various products with leading biology companies such as Novo Nordisk A/S, Merck & Co., Inc., Merck KGaA, AbbVie, Inc., and C.H. Boehringer Sohn AG & Ko. KG.